The Genitourinary Medical Oncology Program focuses on the treatment of testicular cancers (germ cell tumors), bladder cancer, kidney cancer and prostate cancer and works closely with our radiation oncology and urologic colleagues in the multidisciplinary clinics. These multidisciplinary clinics meet weekly to evaluate, discuss and render a comprehensive treatment approach for patients with genitourinary cancers. The medical oncologists in this program are experts in all stages of genitourinary cancers and have access to a wide range of  therapies including dendritic cell based vaccine (Provenge), high dose Interleukin -2, and multiple new investigational drugs (research studies).

Wm. Kevin Kelly, DO leads the program and has an extensive experience developing novel agents for genitourinary cancers from the bench to the bedside. He currently conducts multiple national and international studies. His research interest includes developing less toxic therapies for patients and developing methods to individualize treatment for patients.

William Tester, MD, FACP is director of bladder cancer research at Jefferson. He has extensive experience in the conduct of clinical trials for patients with locally advanced or metastatic bladder cancer. He has also taken a lead role in working with the SKCCC Phase 1 program screening new agents for the treatment of urologic cancer. 

Kevin Kayvan Zarrabi, MD MS FACP, is an Assistant Professor and medical oncologist with a clinical and research focus on genitourinary malignancies. Dr. Zarrabi serves as a principal investigator of numerous clinical studies, including investigator-initiated clinical trials. He has a focus on developing novel treatment approaches for patients with advanced disease, as well as identification of biomarkers to assist in clinical decision making.